These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9158191)

  • 1. Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer.
    Pålsson B; Masson P; Andrén-Sandberg A
    Eur J Surg Oncol; 1997 Apr; 23(2):151-6. PubMed ID: 9158191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of the CA 19-9 tumor marker in differential diagnosis of space-occupying lesions in the head of the pancreas].
    Böttger T; Hassdenteufel A; Boddin J; Küchle R; Junginger T; Prellwitz W
    Chirurg; 1996 Oct; 67(10):1007-11. PubMed ID: 9011418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and therapeutic dilemmas in periampullary lesions.
    Tsai PJ; Wang SE; Shyr YM; Chen TH; Su CH; Wu CW
    Hepatogastroenterology; 2012; 59(117):1621-5. PubMed ID: 22683981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ca 19-9 in the diagnosis of pancreatic carcinoma].
    Meggiato T; Basso D; Pasquali C; Angonese C; Bellinvia S; Del Favero G; Fabris C; Di Mario F; Plebani M; Pedrazzoli S
    Minerva Med; 1989 May; 80(5):431-4. PubMed ID: 2747969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.
    Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; van Dalen A; Einarsson R
    Cancer; 2000 Jul; 89(1):83-8. PubMed ID: 10897004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA 242 is a new tumor marker for pancreatic cancer.
    Röthlin MA; Joller H; Largiadèr F
    Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CA 242: the search for a valid marker of pancreatic cancer.
    Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
    Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy.
    DelMaschio A; Vanzulli A; Sironi S; Castrucci M; Mellone R; Staudacher C; Carlucci M; Zerbi A; Parolini D; Faravelli A
    Radiology; 1991 Jan; 178(1):95-9. PubMed ID: 1984331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is jaundice a cause of error in the interpretation of CA 19-9 blood levels?].
    Nakad A; Colombel JF; Geubel AP; Cerulus G; Farchakh E; Degrez T; Janssen J; Cortot A; Paris JC; Dive C
    Acta Gastroenterol Belg; 1989; 52(1-2):17-22. PubMed ID: 2618531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
    Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F; Büchler M; Schenkluhn B; Beger HG
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
    Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
    Pålsson B; Masson P; Andrén-Sandberg A
    Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.